Metabolic inflexibility of mitochondria: beneficial for the fitness of regenerating liver cells [0.03%]
线粒体代谢刚性利于再生肝细胞的增殖及分化
Josef Ecker,Sarah Brunner,Klaus-Peter Janssen
Josef Ecker
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study [0.03%]
抗PD-L1抗体ASC22联合组蛋白脱乙酰酶抑制剂氯達敏作为“唤醒与杀死”的策略实现停用ART的病毒学控制：一项二期、单臂研究
Luling Wu,Zhihang Zheng,Jingna Xun et al.
Luling Wu et al.
The combination of ASC22, an anti-PD-L1 antibody potentially enhancing HIV-specific immunity and chidamide, a HIV latency reversal agent, may serve as a strategy for antiretroviral therapy-free virological control for HIV. People living wit...
A new paradigm for generating high-quality cardiac pacemaker cells from mouse pluripotent stem cells [0.03%]
一种通过从小鼠多能干细胞生成高质量心脏起搏器细胞的新范式
Zheyi Lin,Bowen Lin,Chengwen Hang et al.
Zheyi Lin et al.
Cardiac biological pacing (BP) is one of the future directions for bradyarrhythmias intervention. Currently, cardiac pacemaker cells (PCs) used for cardiac BP are mainly derived from pluripotent stem cells (PSCs). However, the production of...
Elimination of mutant SWI/SNF complexes by protein quality control: new opportunities targeting aggressive rhabdoid tumours [0.03%]
蛋白质质量控制消除突变型SWI/SNF复合物：治疗侵袭性肿瘤的新策略
Andreas Krämer,Stefan Knapp
Andreas Krämer
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study [0.03%]
特瑞普利单抗联合大剂量甲氨蝶呤、替莫唑胺及奥妥珠单抗治疗原发中枢神经系统淋巴瘤的Ⅱ期临床研究
Zhiyong Zeng,Apeng Yang,Jingke Yang et al.
Zhiyong Zeng et al.
Primary central nervous system lymphoma (PCNSL) is a rare and frequently fatal lymphoma subtype. The programmed death-1 (PD-1) pathway has emerged as a potential therapeutic target, but the effectiveness of PD-1 antibody sintilimab in combi...
"Clone-specific" antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers [0.03%]
“克隆特异性”抗体-药物偶联物：T细胞肿瘤治疗的创新策略
Dennis Jungherz,Philipp Lückemeier,Marco Herling
Dennis Jungherz
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation [0.03%]
特瑞普利单抗治疗聚合酶ε/δ(POL E/D)突变的晚期实体瘤的II期临床研究
Ying Jin,Run-Jie Huang,Wen-Long Guan et al.
Ying Jin et al.
Patients carrying mutations in polymerase epsilon/polymerase delta have shown positive responses to immune checkpoint inhibitors. Yet, prospective trials exploring the efficacy in those with polymerase epsilon/polymerase delta mutations are...
Circulating tumor cells: from new biological insights to clinical practice [0.03%]
循环肿瘤细胞：从新的生物学认识至临床实践
Xuyu Gu,Shiyou Wei,Xin Lv
Xuyu Gu
The primary reason for high mortality rates among cancer patients is metastasis, where tumor cells migrate through the bloodstream from the original site to other parts of the body. Recent advancements in technology have significantly enhan...
Maria-Luise Petrovic-Erfurth,Albena Jordanova
Maria-Luise Petrovic-Erfurth
Opioid receptors: single molecule studies shed light on mechanisms of efficacy [0.03%]
阿片受体：单分子研究揭示疗效机制
Cornelius Krasel,Moritz Bünemann
Cornelius Krasel